New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
08:18 EDTPCYCPharmacyclics reports sNDA for Imbruvica accepted, priority review granted
Pharmacyclics announced that the FDA has accepted for filing its suplemental new drug application to support the review of Imbruvica in the treatment of patients with CLL and SLL who have received at least one prior therapy for a full approval. The target PDUFA date by which the FDA is planning to finalize the review of this application is October 7.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
07:35 EDTPCYCPharmacyclics Imbruvica.checks positive, says Deutsche Bank
Subscribe for More Information
August 19, 2014
14:11 EDTPCYCPharmacyclics weakness on safety issues overdone, says Deutsche Bank
Subscribe for More Information
August 18, 2014
16:08 EDTPCYCPharmacyclics names Shawn Cline Tomasello as Chief Commercial Officer
Cline Tomasello is a 30-year industry veteran and former President of the Americas, Hematology and Oncology, for the Celgene Corporation, where she managed over $4B in revenue. Prior to joining Celgene, Cline Tomasello was the National Director of Hematology for Rituxan at Genentech, where she was responsible for over $1.7B in revenue.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use